Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Febrile Neutropenia 2Polycystic Ovary Syndrome 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Inflammation 1Hematologic Neoplasms 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Cytokine Release Syndrome 1Colorectal Neoplasms 1Burkitt Lymphoma 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 59Dexamethasone 56Melphalan 48Peripheral Blood Stem Cell Transplantation 37Busulfan 34Bortezomib 32fludarabine phosphate 29Lenalidomide 27Filgrastim 27Tacrolimus 24Antilymphocyte Serum 24Thalidomide 22Mycophenolic Acid 22Radiotherapy 21Methotrexate 15Cyclosporine 15Etoposide 14sargramostim 13Granulocyte Colony-Stimulating Factor 11Whole-Body Irradiation 10Methylprednisolone 10Interferon-alpha 10fludarabine 9daratumumab 9Carmustine 9carfilzomib 7Rituximab 7Prednisone 7Cytarabine 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Plasma Cell × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT00635154 2018-06-07

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Mayo Clinic

Phase 2 Completed
55 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡